The Medical University of Innsbruck is a university in Innsbruck, Austria. It used to be one of the four historical faculties of the Leopold-Franzens-Universität Innsbruck and became an independent university in 2004.

During the past decade, Medical University Innsbruck conducted 125 clinical trials. In the 10-year time frame, 125 clinical trials started and 21 clinical trials were completed, i.e. on average, 16.8% percent of trials that started reached the finish line to date. In the past 5 years, 55 clinical trials started and 15 clinical trials were completed. i.e. 27.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Medical University Innsbruck" #1 sponsor was "Medical University Innsbruck" with 49 trials, followed by "Boehringer Ingelheim" with 10 trials sponsored, "Celgene" with 8 trials sponsored, "Medical University of Graz" with 5 trials sponsored and "AO Clinical Investigation and Publishing Documentation" with 5 trials sponsored. Other sponsors include 90 different institutions and companies that sponsored additional 84 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Medical University Innsbruck" #1 collaborator was "Medical University Innsbruck" with 14 trials as a collaborator, "Medical University of Vienna" with 7 trials as a collaborator, "Hoffmann-La Roche" with 4 trials as a collaborator, "Paracelsus Medical University" with 3 trials as a collaborator and "Amgen" with 2 trials as a collaborator. Other collaborators include 178 different institutions and companies that were collaborators in the rest 176 trials.

According to Clinical.Site data, the most researched conditions in "Medical University Innsbruck" are "Atherosclerosis" (6 trials), "Coronary Artery Disease" (5 trials), "Heart Failure" (5 trials), "Parkinson Disease" (5 trials) and "COVID-19" (4 trials). Many other conditions were trialed in "Medical University Innsbruck" in a lesser frequency.

Most popular intervention types in "Medical University Innsbruck" are "Drug" (66 trials), "Device" (35 trials), "Other" (32 trials), "Procedure" (20 trials) and "Diagnostic Test" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Surgery" (4 trials), "Gemcitabine" (3 trials), "Ozanimod" (3 trials) and "BI 425809 dose 1" (2 trials). Other intervention names were less common.

The vast majority of trials in "Medical University Innsbruck" are 147 trials for "All" genders, 21 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Medical University Innsbruck". 4 are not yet recruiting, 42 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 72 completed trials in Medical University Innsbruck, 2 suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in Medical University Innsbruck, 8 "Phase 1" clinical trials were conducted, 27 "Phase 2" clinical trials and 38 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 45 trials that are defined as “Not Applicable".